

Revvity, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES ⁽¹⁾

(In millions, except per share data and percentages)

Adjusted revenue:

Revenue
Purchase accounting adjustments
Adjusted revenue

Adjusted gross margin:

Gross margin
Amortization of intangible assets
Purchase accounting adjustments
Acquisition and divestiture-related costs
Adjusted gross margin

Adjusted SG&A:

SG&A
Amortization of intangible assets
Purchase accounting adjustments
Acquisition and divestiture-related costs
Asset impairment
Significant litigation matters and settlements
Significant environmental matters
Restructuring and other, net
Adjusted SG&A

Adjusted R&D:

R&D
Purchase accounting adjustments
Acquisition and divestiture-related costs
Adjusted R&D

Adjusted operating income:

Operating income
Amortization of intangible assets
Purchase accounting adjustments
Acquisition and divestiture-related costs
Asset impairment
Significant litigation matters and settlements
Significant environmental matters
Restructuring and other, net
Adjusted operating income

Adjusted EPS:

GAAP EPS
Discontinued operations, net of income taxes
GAAP EPS from continuing operations
Amortization of intangible assets
Debt extinguishment costs
Purchase accounting adjustments
Acquisition and divestiture-related costs
Change in fair value of financial securities
Asset impairment
Significant litigation matters and settlements
Significant environmental matters
Mark to market on postretirement benefits
Restructuring and other, net
Tax on above items
Significant tax items
Adjusted EPS

Revvity					
Three Months Ended					
December 29, 2024			December 31, 2023		
\$	729.4		\$	695.9	
	0.2			0.2	
\$	729.6		\$	696.1	
\$	412.3	56.5%	\$	383.5	55.1%
	35.3	4.8%		34.6	5.0%
	0.3	0.0%		0.3	0.1%
	0.0	0.0%		0.3	0.0%
\$	447.9	61.4%	\$	418.8	60.2%
\$	244.3	33.5%	\$	256.7	36.9%
	(52.6)	-7.2%		(55.0)	-7.9%
	7.8	1.1%		(2.5)	-0.4%
	(3.1)	-0.4%		(9.0)	-1.3%
	(22.8)	-3.1%		-	0.0%
	(0.7)	-0.1%		(0.0)	0.0%
	-	0.0%		(1.3)	-0.2%
	4.7	0.6%		(10.7)	-1.5%
\$	177.6	24.3%	\$	178.3	25.6%
\$	49.2	6.7%	\$	49.6	7.1%
	(0.1)	0.0%		(0.1)	0.0%
	(0.1)	0.0%		(0.8)	-0.1%
\$	49.0	6.7%	\$	48.7	7.0%
\$	118.8	16.3%	\$	77.2	11.1%
	87.9	12.0%		89.6	12.9%
	(7.4)	-1.0%		2.9	0.4%
	3.3	0.4%		10.1	1.4%
	22.8	3.1%		-	0.0%
	0.7	0.1%		0.0	0.0%
	-	0.0%		1.3	0.2%
	(4.7)	-0.6%		10.7	1.5%
\$	221.3	30.3%	\$	191.8	27.5%

Revvity			
Three Months Ended			
December 29, 2024		December 31, 2023	
\$	0.78	\$	0.64
	0.05		0.12
	0.73		0.52
	0.72		0.73
	-		(0.00)
	(0.06)		0.02
	0.03		0.08
	0.05		0.17
	0.19		-
	0.01		0.00
	-		0.01
	0.01		0.08
	(0.04)		0.09
	(0.21)		(0.29)
	-		(0.14)
\$	1.42	\$	1.25

(1) amounts may not sum due to rounding

Revvity, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES ⁽¹⁾

(In millions, except per share data and percentages)

Adjusted revenue:

Revenue
Purchase accounting adjustments
Adjusted revenue

Adjusted gross margin:

Gross margin
Amortization of intangible assets
Purchase accounting adjustments
Acquisition and divestiture-related costs
Adjusted gross margin

Adjusted SG&A:

SG&A
Amortization of intangible assets
Purchase accounting adjustments
Acquisition and divestiture-related costs
Asset impairment
Significant litigation matters and settlements
Significant environmental matters
Restructuring and other, net
Adjusted SG&A

Adjusted R&D:

R&D
Purchase accounting adjustments
Acquisition and divestiture-related costs
Adjusted R&D

Adjusted operating income:

Operating income
Amortization of intangible assets
Purchase accounting adjustments
Acquisition and divestiture-related costs
Asset impairment
Significant litigation matters and settlements
Significant environmental matters
Restructuring and other, net
Adjusted operating income

Adjusted EPS:

GAAP EPS
Discontinued operations, net of income taxes
GAAP EPS from continuing operations
Amortization of intangible assets
Debt extinguishment costs
Purchase accounting adjustments
Acquisition and divestiture-related costs
Change in fair value of financial securities
Asset impairment
Significant litigation matters and settlements
Significant environmental matters
Mark to market on postretirement benefits
Restructuring and other, net
Tax on above items
Significant tax items
Adjusted EPS

Revvity					
Twelve Months Ended					
December 29, 2024			December 31, 2023		
\$	2,755.0		\$	2,750.6	
	0.8			0.8	
\$	2,755.9		\$	2,751.4	
\$	1,537.7	55.8%	\$	1,539.7	56.0%
	144.4	5.2%		147.6	5.4%
	1.4	0.1%		1.4	0.1%
	6.8	0.2%		2.8	0.1%
\$	1,690.2	61.3%	\$	1,691.5	61.5%
\$	994.1	36.1%	\$	1,022.6	37.2%
	(215.0)	-7.8%		(217.5)	-7.9%
	1.7	0.1%		(4.3)	-0.2%
	(16.3)	-0.6%		(62.0)	-2.3%
	(22.8)	-0.8%		-	0.0%
	(7.8)	-0.3%		(0.0)	0.0%
	-	0.0%		(2.5)	-0.1%
	(17.5)	-0.6%		(26.6)	-1.0%
\$	716.4	26.0%	\$	709.6	25.8%
\$	196.8	7.1%	\$	216.6	7.9%
	(0.2)	0.0%		(0.2)	0.0%
	(2.2)	-0.1%		(4.3)	-0.2%
\$	194.4	7.1%	\$	212.0	7.7%
\$	346.7	12.6%	\$	300.6	10.9%
	359.4	13.0%		365.1	13.3%
	(0.1)	0.0%		6.0	0.2%
	25.4	0.9%		69.2	2.5%
	22.8	0.8%		-	0.0%
	7.8	0.3%		0.0	0.0%
	-	0.0%		2.5	0.1%
	17.5	0.6%		26.6	1.0%
\$	779.5	28.3%	\$	769.9	28.0%

Revvity					
Twelve Months Ended					
December 29, 2024			December 31, 2023		
\$	2.20		\$	5.55	
	(0.10)			4.11	
	2.30			1.44	
	2.93			2.93	
	-			(0.03)	
	(0.00)			0.05	
	0.16			0.71	
	(0.06)			0.27	
	0.19			-	
	0.06			0.00	
	-			0.02	
	0.01			0.08	
	0.14			0.21	
	(0.83)			(1.02)	
	-			(0.01)	
\$	4.90		\$	4.65	

(1) amounts may not sum due to rounding

Revvity, Inc. and Subsidiaries
ADJUSTED NET INTEREST AND OTHER EXPENSE

(In millions)

Adjusted net interest and other expense:

Net interest and other expense
Less divestiture-related interest income
Less pension mark to market
Less change in fair value of financial securities
Less disposition related FX net loss
Adjusted net interest and other expense

Revvity	
Three Months Ended	
<u>December 29, 2024</u>	
\$	24
	1
	1
	6
	0
\$	17

Revvity	
Twelve Months Ended	
<u>December 29, 2024</u>	
\$	31
	(4)
	1
	(8)
	(1)
\$	43

(1) amounts may not sum due to rounding

Revvity, Inc. and Subsidiaries
RECONCILIATION OF GAAP TAX RATE TO ADJUSTED TAX RATE ⁽¹⁾

(In millions, except tax rates)

	Revvity Three Months Ended December 29, 2024			Revvity Twelve Months Ended December 29, 2024		
	<u>Continuing Operations</u>	<u>Non-GAAP Adjusting Items</u>	<u>Adjusted Continuing Operations</u>	<u>Continuing Operations</u>	<u>Non-GAAP Adjusting Items</u>	<u>Adjusted Continuing Operations</u>
Income before income taxes	\$ 94.6	\$ 110.2	\$ 204.8	\$ 316.1	420.4	\$ 736.5
Provision for income taxes	6.2	25.9	32.1	\$ 33.1	102.2	\$ 135.3
Net income	<u>\$ 88.4</u>	<u>\$ 84.3</u>	<u>\$ 172.7</u>	<u>\$ 283.1</u>	<u>318.2</u>	<u>\$ 601.2</u>
Tax rate	6.5%		15.7%	10.5%		18.4%

(1) amounts may not sum due to rounding

Revvity, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES ⁽¹⁾

Continuing Operations	
Three Months Ended December 29, 2024	
	5%
	-1%
	0%
	6%

Organic revenue growth:

Reported revenue growth from continuing operations
Less: effect of foreign exchange rates
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses
Organic revenue growth from continuing operations

Life Sciences	
Three Months Ended December 29, 2024	
	5%
	0%
	0%
	5%

Organic revenue growth:

Reported revenue growth from continuing operations
Less: effect of foreign exchange rates
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses
Organic revenue growth from continuing operations

Diagnostics	
Three Months Ended December 29, 2024	
	4%
	-1%
	0%
	6%

Organic revenue growth:

Reported revenue growth from continuing operations
Less: effect of foreign exchange rates
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses
Organic revenue growth from continuing operations

(1) amounts may not sum due to rounding

Revvity, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES ⁽¹⁾

Organic revenue growth:

Reported revenue growth from continuing operations
Less: effect of foreign exchange rates
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses
Organic revenue growth from continuing operations

Continuing Operations	
Twelve Months Ended December 29, 2024	
	0%
	0%
	0%
	1%

Organic revenue growth:

Reported revenue growth from continuing operations
Less: effect of foreign exchange rates
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses
Organic revenue growth from continuing operations

Life Sciences	
Twelve Months Ended December 29, 2024	
	-3%
	0%
	0%
	-3%

Organic revenue growth:

Reported revenue growth from continuing operations
Less: effect of foreign exchange rates
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses
Organic revenue growth from continuing operations

Diagnostics	
Twelve Months Ended December 29, 2024	
	3%
	-1%
	0%
	4%

(1) amounts may not sum due to rounding

Revvity, Inc. and Subsidiaries
FY 2025 ORGANIC REVENUE GROWTH FORECAST ⁽¹⁾

Organic revenue growth:

Reported revenue growth from continuing operations

Less: effect of foreign exchange rates

Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

Organic revenue growth from continuing operations

Continuing Operations	
Twelve Months Ending December 28, 2025	
Projected	
	1.5% - 3.5%
	-1.5%
	0.0%
	3.0% - 5.0%

(1) amounts may not sum due to rounding

Revvity, Inc. and Subsidiaries
NET DEBT TO ADJUSTED EBITDA RATIO ⁽¹⁾

(In millions, except ratio)

Net income from continuing operations	
Income taxes	
Purchase accounting adjustments	
Acquisition and divestiture-related costs	
Change in fair value of financial securities	
Mark to market on post-retirement benefits	
Restructuring and other, net	
Significant litigation matters and settlements	
Stock-based compensation	
Interest expense, net	
Depreciation	
Amortization of intangible assets	
Asset impairments	
Adjusted EBITDA	

Revvity	
Twelve Months Trailing December 29, 2024	
\$	283.1
	33.1
	(1.0)
	14.1
	(8.0)
	1.0
	17.5
	7.8
	37.8
	23.1
	68.5
	359.4
	22.8
\$	859.1

Cash and cash equivalents as of December 29, 2024	
Gross debt as of December 29, 2024	
Net debt as of December 29, 2024	

\$	1,163.4
	3,150.7
\$	1,987.3
	2.3 times

Net Debt to adjusted EBITDA Ratio

(1) amounts may not sum due to rounding

Revvity, Inc. and Subsidiaries
FREE CASH FLOW AS A PERCENT OF ADJUSTED NET INCOME

(In thousands, except percentages)

Free cash flow

Net cash provided by operating activities of continuing operations
Less capital expenditures
Free cash flow from continuing operations

Income from continuing operations

Amortization of intangible assets
Mark to market and curtailments on postretirement benefits
Purchase accounting adjustments
Acquisition and divestiture-related costs
Asset impairment
Significant litigation matters and settlements
Restructuring and other, net
Change in fair value of financial securities
Tax on above items
Adjusted net income

Revvity	
Three Months Ended December 29, 2024	
\$	175,467
	(24,454)
	151,013
	88,383
	87,876
	1,010
	(7,427)
	3,921
	22,814
	689
	(4,665)
	6,017
	(25,907)
\$	172,711

Revvity	
Twelve Months Ended December 29, 2024	
\$	664,955
	(86,648)
	578,307
	283,071
	359,376
	1,010
	(79)
	20,012
	22,814
	7,775
	17,454
	(7,958)
	(102,236)
\$	601,239

Free cash flow as a percentage of adjusted net income

87%

96%

(1) amounts may not sum due to rounding

Revvity, Inc. and Subsidiaries
RECAST OF SEGMENT REVENUE AND SEGMENT OPERATING INCOME ⁽¹⁾

	Twelve Months Ended	Three Month Ended				Twelve Months Ended
(In thousands, except percentages)	Dec. 31, '23	Mar. 31, '24	Jun. 30, '24	Sep. 29, '24	Dec. 29, '24	Dec. 29, '24
Segment Revenue						
Life Sciences	\$ 1,458,192	336,514	348,525	338,800	374,762	\$ 1,398,601
Diagnostics	\$ 1,293,206	313,615	343,367	345,454	354,818	\$ 1,357,254
Revenue purchase accounting adjustments	\$ (827)	(209)	(207)	(205)	(208)	\$ (829)
Reported Revenue	\$ 2,750,571	649,920	691,685	684,049	729,372	\$ 2,755,026
Segment Operating Income						
Life Sciences	\$ 512,250	100,951	117,567	110,565	138,193	467,276
<i>% of Revenue</i>	35%	30%	34%	33%	37%	33%
Diagnostics	298,027	76,204	92,749	93,848	91,137	353,938
<i>% of Revenue</i>	23%	24%	27%	27%	26%	26%
Corporate	(40,417)	(11,361)	(11,449)	(10,915)	(8,029)	(41,754)
Total reportable segments operating income	\$ 769,860	165,794	198,867	193,498	221,301	779,460
<i>% of Revenue</i>	28.0%	25.5%	28.8%	28.3%	30.3%	28.3%

(1) The information presented is a preliminary estimate and subject to change. The re-segmentation will be effective as of December 30, 2024.

Revvity, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES ⁽¹⁾⁽²⁾
RECAST OF SEGMENT ORGANIC GROWTH RECONCILIATIONS

Organic revenue growth:

Reported revenue growth from continuing operations
Less: effect of foreign exchange rates
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses
Organic revenue growth from continuing operations
Less: effect of COVID products
Non-COVID organic revenue growth from continuing operations

Continuing Operations					
Twelve Months Ended Dec. 31, '23	Three Months Ended				Twelve Months Ended Dec. 29, '24
	Mar. 31, '24	Jun. 30, '24	Sep. 29, '24	Dec. 29, '24	
-17%	-4%	-2%	2%	5%	0%
0%	0%	-1%	0%	-1%	0%
0%	0%	0%	0%	0%	0%
-16%	-3%	-1%	2%	6%	1%
-19%	0%	0%	0%	0%	0%
2%	-3%	-1%	2%	6%	1%

Organic revenue growth:

Reported revenue growth from continuing operations
Less: effect of foreign exchange rates
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses
Organic revenue growth from continuing operations
Less: effect of COVID products
Non-COVID organic revenue growth from continuing operations

Life Sciences					
Twelve Months Ended Dec. 31, '23	Three Months Ended				Twelve Months Ended Dec. 29, '24
	Mar. 31, '24	Jun. 30, '24	Sep. 29, '24	Dec. 29, '24	
-3%	-10%	-8%	-2%	4%	-4%
0%	0%	-1%	0%	0%	0%
0%	0%	0%	0%	0%	0%
-3%	-10%	-8%	-3%	5%	-4%
-2%	0%	0%	0%	0%	0%
-1%	-10%	-8%	-3%	5%	-4%

Organic revenue growth:

Reported revenue growth from continuing operations
Less: effect of foreign exchange rates
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses
Organic revenue growth from continuing operations
Less: effect of COVID products
Non-COVID organic revenue growth from continuing operations

Diagnostics					
Twelve Months Ended Dec. 31, '23	Three Months Ended				Twelve Months Ended Dec. 29, '24
	Mar. 31, '24	Jun. 30, '24	Sep. 29, '24	Dec. 29, '24	
-29%	4%	4%	7%	5%	5%
-1%	-1%	-2%	0%	-1%	-1%
0%	0%	0%	0%	0%	0%
-28%	4%	6%	6%	6%	6%
-34%	-1%	0%	0%	0%	0%
7%	6%	6%	6%	6%	6%

(1) Amounts may not sum due to rounding

(2) The information presented is a preliminary estimate and subject to change. The re-segmentation will be effective as of December 30, 2024.

Explanation of Non-GAAP Financial Measures

We report our financial results in accordance with GAAP. However, management believes that, in order to more fully understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash, non-recurring or other items, which result from facts and circumstances that vary in frequency and impact on continuing operations. Accordingly, we present non-GAAP financial measures as a supplement to the financial measures we present in accordance with GAAP. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by adjusting for certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management's ability to make useful forecasts. Management believes these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

We use the term “adjusted revenue” to refer to GAAP revenue, including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term “adjusted revenue growth” to refer to the measure of comparing current period adjusted revenue with the corresponding period of the prior year.

We use the term “organic revenue” to refer to GAAP revenue, excluding the effect of foreign currency changes and revenue from recent acquisitions and divestitures and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term “organic revenue growth” or “organic growth” to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year. We use the related term “non-COVID organic revenue growth” to refer to the measure of comparing current period organic revenue excluding revenue from COVID related products and services with the corresponding period of the prior year excluding revenue from COVID related products and services.

We use the term “adjusted gross margin” to refer to GAAP gross margin, excluding amortization of intangible assets and inventory fair value adjustments related to business acquisitions, asset impairments, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to business combination accounting rules. We use the related term “adjusted gross margin percentage” to refer to adjusted gross margin as a percentage of adjusted revenue.

We use the term “adjusted SG&A expense” to refer to GAAP SG&A expense, excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, asset impairments, significant environmental charges, and restructuring and other charges. We use the related term “adjusted SG&A percentage” to refer to adjusted SG&A expense as a percentage of adjusted revenue.

We use the term “adjusted R&D expense” to refer to GAAP R&D expense, excluding amortization of intangible assets and purchase accounting adjustments. We use the related term “adjusted R&D percentage” to refer to adjusted R&D expense as a percentage of adjusted revenue.

We use the term “adjusted net interest and other expense” to refer to GAAP net interest and other expense, excluding adjustments for mark-to-market accounting on post-retirement benefits, changes in foreign exchange and interest associated with acquisitions and divestitures, changes in the value of financial securities and debt extinguishment costs.

We use the term “adjusted operating income” to refer to GAAP operating income, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, asset impairments, and restructuring and other charges. We use the related terms “adjusted operating profit percentage,” “adjusted operating profit margin,” and “adjusted operating margin” to refer to adjusted operating income as a percentage of adjusted revenue.

We use the term “free cash flow” to refer net cash provided by (used in) operating activities of continuing operations, less payments for additions to property, plant and equipment from continuing operations (“capital expenditures”) plus the proceeds from sales of plant, property and equipment from continuing operations (“capital disposals”).

We use the term “adjusted net income,” to refer to GAAP income from continuing operations, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, changes in the value of financial securities, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

We use the term “adjusted earnings per share from continuing operations”, “adjusted earnings per share,” “adjusted EPS,” or “adjusted EPS from continuing operations” to refer to GAAP earnings per share from continuing operations, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, changes in the value of financial securities, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

Management includes or excludes the effect of each of the items identified below in the applicable non-GAAP financial measure referenced above for the reasons set forth below with respect to that item:

- Amortization of intangible assets—purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such

charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

- Debt extinguishment costs—we incur costs and income related to the extinguishment of debt; including make-whole payments to debt holders, accelerated amortization of debt fees and discounts, and expense or income from hedges to lock in make-whole payments. We exclude the impact of these items from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
- Revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules—accounting rules require us to account for the fair value of revenue from contracts assumed in connection with our acquisitions. As a result, our GAAP results reflect the fair value of those revenues, which is not the same as the revenue that otherwise would have been recorded by the acquired entity. We include such revenue in our non-GAAP measures because we believe the fair value of such revenue does not accurately reflect the performance of our ongoing operations for the period in which such revenue is recorded.
- Other purchase accounting adjustments—accounting rules require us to adjust various balance sheet accounts, including inventory, fixed assets and deferred rent balances to fair value at the time of the acquisition. As a result, the expenses for these items in our GAAP results are not the same as what would have been recorded by the acquired entity. Accounting rules also require us to estimate the fair value of contingent consideration at the time of the acquisition, and any subsequent changes to the estimate or payment of the contingent consideration and purchase accounting adjustments are charged to expense or income. We exclude the impact of any changes to contingent consideration from our non-GAAP measures because we believe these expenses or benefits do not accurately reflect the performance of our ongoing operations for the period in which such expenses or benefits are recorded.
- Acquisition and divestiture-related expenses—we incur legal, due diligence, stay bonuses, incentive awards, stock-based compensation, interest, foreign exchange gains and losses, integration expenses, rebranding expenses, and other costs related to acquisitions and divestitures. We exclude these expenses from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
- Asset impairments—we incur expense related to asset impairments. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
- Restructuring and other charges—restructuring and other charges consist of employee severance, other exit costs as well as the cost of terminating certain lease agreements or contracts as well as costs associated with relocating facilities. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are reported.
- Adjustments for mark-to-market accounting on post-retirement benefits—we exclude adjustments for mark-to-market accounting on post-retirement benefits, and therefore only our projected costs are used to calculate our non-GAAP measures. We exclude these adjustments because they do not represent what we believe our investors consider to be costs of producing our products, investments in technology and production, and costs to support our internal operating structure.
- Significant litigation matters and settlements—we incur expenses related to significant litigation matters, including the costs to settle or resolve various claims and legal proceedings. Management does not believe

such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.

- Significant environmental charges—we incur expenses related to significant environmental charges. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
- Disposition of businesses and assets, net—we exclude the impact of gains or losses from the disposition of businesses and assets from our adjusted earnings per share. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.
- Impact of foreign currency changes on the current period—we exclude the impact of foreign currency associated with acquisitions and divestitures from these measures by using the prior period's foreign currency exchange rates for the current period because foreign currency exchange rates are subject to volatility and can obscure underlying trends.
- Impact of significant tax events—we exclude the impact of significant tax events. Management does not believe the impact of significant tax events accurately reflects the performance of our ongoing operations for the periods in which the impact of such events was recorded.
- Changes in value of financial securities—we exclude the impact of changes in the value of financial securities. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.

#

The tax effect for discontinued operations is calculated based on the authoritative guidance in the Financial Accounting Standards Board's Accounting Standards Codification 740, Income Taxes. The tax effect for amortization of intangible assets, inventory fair value adjustments related to business acquisitions, changes to the fair values assigned to contingent consideration, debt extinguishment costs, other costs related to business acquisitions and divestitures, significant litigation matters and settlements, significant environmental charges, changes in the fair value of financial securities, adjustments for mark-to-market accounting on post-retirement benefits, disposition of businesses and assets, net, restructuring and other charges, and the revenue from contracts acquired with various acquisitions is calculated based on operational results and applicable jurisdictional law, which contemplates tax rates currently in effect to determine our tax provision. The tax effect for the impact from foreign currency exchange rates on the current period is calculated based on the average rate currently in effect to determine our tax provision.

The non-GAAP financial measures described above are not meant to be considered superior to, or a substitute for, our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude charges that have an effect on our reported results and, therefore, should not be relied upon as the sole financial measures by which to evaluate our financial results. Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies.

Each of the non-GAAP financial measures listed above is also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, benchmark our results against our historical performance and the performance of our peers, evaluate investment opportunities including acquisitions and discontinued operations, and determine the bonus payments for senior management and employees.

Investor Relations:

Steve Willoughby
steve.willoughby@revvity.com

Media Relations:

Chet Murray
(781) 462-5126
chet.murray@revvity.com